Who Paid My Doc
Zarqa Imdad
Infectious Disease Elgin, IL Medical Doctor
NPI 1689660995 CMS profile 1094433
2130 Point Blvd, Ste 900, Elgin, IL 60123
General payments
$12
Research payments
$0
Ownership & investment interest
$0
Through program year 2021, Zarqa Imdad of Elgin, IL is reported in the CMS Open Payments database as having received $12 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 1st percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2021 | General | $12 | 1 |
Beside peers
- Zarqa Imdad
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Zarqa Imdad were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Zarqa Imdad | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $190 | $60–$862 | $163 |
| 2020 | $0 | $124 | $32–$606 | $114 |
| 2021 | $12 | $148 | $38–$905 | $132 |
| 2022 | $0 | $166 | $50–$834 | $149 |
| 2023 | $0 | $171 | $57–$787 | $160 |
| 2024 | $0 | $176 | $52–$752 | $164 |
| 2025 | $0 | $188 | $57–$766 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 21 drugsPart D claims
535
Drug cost
$169,729
Branded share of claims
32%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 32 | $139,361 | |
| Piperacillin-Tazobactam Piperacillin Sodium/Tazobactam | Brand | 14 | $5,354 | |
| Meropenem | Generic | 20 | $5,086 | |
| Ertapenem Ertapenem Sodium | Brand | 12 | $3,530 | |
| Vancomycin Hcl | Generic | 24 | $2,953 | |
| Cefuroxime Cefuroxime Axetil | Brand | 62 | $2,881 | |
| Doxycycline Monohydrate | Generic | 34 | $2,431 | |
| Cefadroxil | Generic | 110 | $1,807 | |
| Ampicillin Sodium | Generic | 11 | $1,606 | |
| Cefepime Hcl | Generic | 16 | $1,521 |
The 10 drugs with the highest cost, of 21 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 63 billing codesPaid by Medicare
$2,086,790
Medicare patients
812
Services billed
118,076
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 65% | |
| Diabetes | 50% | |
| Chronic kidney disease | 50% | |
| Ischemic heart disease | 46% | |
| Heart failure | 45% | |
| Depression | 39% | |
| Atrial fibrillation | 38% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg J1569 | Office | 13 | 7,228 | $256,688 |
| Injection, dalbavancin, 5 mg J0875 | Office | 22 | 6,700 | $81,148 |
| Injection, denosumab, 1 mg J0897 | Office | 31 | 2,400 | $48,379 |
| Injection, infliximab, excludes biosimilar, 10 mg J1745 | Office | 15 | 1,710 | $41,603 |
| Injection, ertapenem sodium, 500 mg J1335 | Office | 14 | 166 | $1,460 |
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 13 | 668 | $239 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Infectious Disease in Illinois
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in Illinois
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.